Acute liver damage and ecstasy ingestion
- PMID: 8675102
- PMCID: PMC1383078
- DOI: 10.1136/gut.38.3.454
Acute liver damage and ecstasy ingestion
Abstract
Eight cases of ecstasy related acute liver damage referred to a specialised liver unit are described. Two patients presented after collapse within six hours of ecstasy ingestion with hyperthermia, hypotension, fitting, and subsequently disseminated intravascular coagulation with rhabdomyolysis together with biochemical evidence of severe hepatic damage. One patient recovered and the other with evidence of hyperacute liver failure was transplanted but subsequently died, histological examination showing widespread microvesicular fatty change. Four patients presented with acute liver failure without hyperthermia. All four fulfilled criteria for transplantation, one died before a donor organ became available, and two died within one month post-transplantation of overwhelming sepsis. Histological examination showed submassive lobular collapse. Two patients presented with abdominal pain and jaundice and recovered over a period of three weeks; histological examination showed a lobular hepatitis with cholestasis. Patients developing jaundice or with evidence of hepatic failure particularly encephalopathy and prolongation of the international normalised ratio, or both, whether or not preceded by hyperthermia, should be referred to a specialised liver unit as liver transplantation probably provides the only chance of recovery.
Similar articles
-
[Acute liver failure following the use of ecstasy (MDMA)].Z Gastroenterol. 2002 Aug;40(8):581-6. doi: 10.1055/s-2002-33416. Z Gastroenterol. 2002. PMID: 12297982 German.
-
Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy.Transpl Int. 1997;10(3):229-33. doi: 10.1007/s001470050047. Transpl Int. 1997. PMID: 9163865 Review.
-
[Variability of the clinical expression of Ecstasy-induced hepatotoxicity].Gastroenterol Hepatol. 2002 Oct;25(8):497-500. doi: 10.1016/s0210-5705(02)70299-9. Gastroenterol Hepatol. 2002. PMID: 12361531 Spanish.
-
Ecstasy induced acute hepatic failure. Case reports.Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):53-5. Acta Gastroenterol Belg. 2015. PMID: 26118578
-
Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option.Vet Hum Toxicol. 2001 Apr;43(2):99-102. Vet Hum Toxicol. 2001. PMID: 11308131 Review.
Cited by
-
Ten years of 'ecstasy'.J R Soc Med. 1999 Feb;92(2):68-72. doi: 10.1177/014107689909200206. J R Soc Med. 1999. PMID: 10450215 Free PMC article. Review. No abstract available.
-
Nephrotoxic effects of designer drugs: synthetic is not better!Nat Rev Nephrol. 2014 Jun;10(6):314-24. doi: 10.1038/nrneph.2014.44. Epub 2014 Mar 25. Nat Rev Nephrol. 2014. PMID: 24662435 Review.
-
Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy).Iran J Basic Med Sci. 2013 Aug;16(8):922-7. Iran J Basic Med Sci. 2013. PMID: 24106597 Free PMC article.
-
Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver.Proteomics. 2008 Sep;8(18):3906-18. doi: 10.1002/pmic.200800215. Proteomics. 2008. PMID: 18780394 Free PMC article.
-
Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System.Front Psychiatry. 2024 Jun 18;15:1414622. doi: 10.3389/fpsyt.2024.1414622. eCollection 2024. Front Psychiatry. 2024. PMID: 38957734 Free PMC article.